. 9 It has also been suggested that median survival can be increased by 5.5% for each 10% increase in maximal cytoreduction. 10 Although initial response rates to cytoreductive surgery and combination chemotherapy are high, the majority of patients will subsequently relapse within three years of diagnosis, and continued disease progression will ultimately lead to death within five years. 11 The value of therapy is often determined using a six-month threshold: if relapse occurs beyond six months, treatment is continued. However, early relapses occurring within six months of initiating therapy are usually unresponsive to re-introduction of platinum-based compounds. Of special interest for clinical researchers is how to optimise the therapeutic index of cancer agents for patients with recurrent ovarian cancer.
survival prognosis and remains a significant threat to women all over the world. Ovarian cancer is the fourth most common cancer of the female reproductive system and represents the highest mortality of all malignancies of the female reproductive system, with 204,000 new cases of ovarian cancer and 125,000 related deaths worldwide each year. 1 Ovarian cancer typically presents vague and non-specific symptoms such as abdominal pain or bloating, urinary symptoms or gastrointestinal symptoms similar to those of irritable bowel syndrome. 2 The exact cause of ovarian cancer remains unknown, although the risk of developing the disease appears to be influenced by many factors, including age, body mass, family history of breast and ovarian cancer and genetic predispositions to other cancers. The risk of ovarian cancer has been shown to be reduced through pregnancy, 3, 4 with each birth reducing the risk by about 12%. 5 The oral contraceptive pill has shown convincing evidence as well, 6 with an estimated risk reduction of 7% for each year of use. 7 Tubal ligations have also been associated with reduced risk of ovarian cancer. 8 
Treatment
Radical cytoreductive surgery and combination chemotherapy with platinum-based compounds and paclitaxel are now recognised as the international standard of care in the first-line setting. Cytoreductive surgery aims to remove as much of the tumour as possible (tumour debulking). 9 It has also been suggested that median survival can be increased by 5.5% for each 10% increase in maximal cytoreduction. 10 Although initial response rates to cytoreductive surgery and combination chemotherapy are high, the majority of patients will subsequently relapse within three years of diagnosis, and continued disease progression will ultimately lead to death within five years. 11 The value of therapy is often determined using a six-month threshold: if relapse occurs beyond six months, treatment is continued. However, early relapses occurring within six months of initiating therapy are usually unresponsive to re-introduction of platinum-based compounds. Of special interest for clinical researchers is how to optimise the therapeutic index of cancer agents for patients with recurrent ovarian cancer.
Topotecan, a topoisomerase-I inhibitor, has been extensively studied in both platinum-resistant and -sensitive relapsed ovarian cancer. Topotecan is one of the most active agents in recurrent ovarian cancer and is a standard therapy for platinum-resistant ovarian cancer patients in many western countries. Topotecan and paclitaxel have been shown to have similar activity in terms of response rates, progression-free survival (PFS) and overall survival (OS), with a demonstrated lack of cross-resistance. 12 However, the severe haematological toxicities associated with topotecan occur at a significantly increased incidence compared with paclitaxel. 13 Conventionally, topotecan is administered following a five-day schedule over a 21-day cycle, but this has been associated with increased bone marrow toxicity, limiting the practicality of using the drug in older patients with low performance status.
In a North-Eastern German Society of Gynaecological Oncology (NOGGO) phase III study, women with recurrent ovarian cancer after primary surgery and platinum therapy were randomised to receive topotecan 1.25mg/m 2 
Topotecan Weekly versus Topotecan Five-day Schedule in Platinum-resistant Ovarian Cancer

Weekly Dosing Schedules
Topotecan given in a weekly schedule is effective in various solid tumours, including cervical, lung and ovarian cancer. Studies have shown that this weekly dosage is better tolerated than the conventional five-day regimen. [15] [16] [17] [18] Similar conclusions were drawn in two retrospective analyses of patients treated with weekly topotecan: comparisons against previously published data for the five-day regimen showed that the weekly administration was just as effective, but had the advantage of presenting with considerably less haematological toxicity. 19, 20 The fact that topotecan is an S-phase-specific agent supports the idea that repeated exposure and dosing can lead to a greater reduction of tumour cells, and suggests that the drug may have schedule-dependent efficacy.
Furthermore, it is known that levels of the targeted topoisomerase-I decrease with prolonged drug exposure, but return to baseline levels in seven days. 21 A weekly regimen might therefore be able to target cells when they are most vulnerable to topotecan. Until recently, there had been no randomised trials that directly compared the weekly topotecan regimen with the five-day therapy. A previous attempt to perform such a comparison in platinum-sensitive patients by the American Gynecologic Oncology Group (GOG) for platinum failed due to slow recruitment, and was prematurely terminated.
The North-Eastern German Society of Gynaecological Oncology -TOWER Study
The 'Topotecan weekly versus routine five-day schedule in patients with 
Patients and Methods
Patients with ovarian and fallopian tube cancers or primary peritoneal carcinoma having failed prior initial therapy with platinum/paclitaxel combination chemotherapy or with response duration less than six months were eligible for the study. Measurable or assessable disease (GCIG-CA-125 response criteria) was required. Patients were randomised to receive topotecan either weekly (d1,8,15/q28d, 4mg/m 2 ) or under the five-day regimen (d1-5/q21d, 1.25mg/m 2 ). The primary end-point was designated as the overall response rate (complete and partial response), with secondary objectives of PFS, OS and quality of life.
Results
In the interim analysis, the median age of the patients was 61 years 
